Malignant mesothelioma (MM) is a highly aggressive tumor with poor prognosis. A major challenge is the development and application of early and highly reliable diagnostic marker(s). Serum biomarkers, such as 'soluble mesothelin-related proteins' (SMRPs), is the most studied and frequently used in MM. However, the low sensitivity of SMRPs for early MM limits its value; therefore, additional biomarkers are required. In this study, two epigenetically regulated markers in MM (microRNA-126, miR-126, and methylated thrombomodulin promoter, Met-TM) were combined with SMRPs and evaluated as a potential strategy to detect MM at an early stage.
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma / Santarelli, Lory; Staffolani, Sara; Strafella, Elisabetta; Nocchi, Linda; Manzella, Nicola; Grossi, Paola; Bracci, Massimo; Pignotti, Elettra; Alleva, Renata; Borghi, Battista; Pompili, Cecilia; Sabbatini, Armando; Rubini, Corrado; Zuccatosta, Lina; Bichisecchi, Elisabetta; Valentino, Matteo; Horwood, Keith; Comar, Manola; Bovenzi, Massimo; Dong, Lan Feng; Neuzil, Jiri; Amati, Monica; Tomasetti, Marco. - In: LUNG CANCER. - ISSN 0169-5002. - 90:3(2015), pp. 457-464. [10.1016/j.lungcan.2015.09.021]